- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT04929041
Afprøvning af tilføjelsen af strålebehandling til den sædvanlige behandling (immunterapi med eller uden kemoterapi) for trin IV ikke-småcellet lungekræftpatienter, der er PD-L1-negative
Et randomiseret fase II/III forsøg med moderne immunterapi baseret systemisk terapi med eller uden SBRT for PD-L1-negativ, avanceret ikke-småcellet lungekræft
This phase II/III trial compares the addition of radiation therapy to the usual treatment (immunotherapy with or without chemotherapy) versus (vs.) usual treatment alone in treating patients with non-small cell lung cancer that may have spread from where it first started to nearby tissue, lymph nodes, or distant parts of the body (advanced) or that has spread from where it first started (primary site) to other places in the body (metastatic) whose tumor is also negative for a molecular marker called PD-L1. Radiation therapy uses high energy x-rays, particles, or radioactive seeds to kill tumor cells and shrink tumors. Immunotherapy with monoclonal antibodies, such as nivolumab, ipilimumab may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. The addition of radiation therapy to usual treatment may stop the cancer from growing and increase the life of patients with advanced non-small cell lung cancer who are PD-L1 negative.
Studieoversigt
Status
Betingelser
Intervention / Behandling
- Andet: Quality-of-Life Assessment
- Procedure: Biospecimen Collection
- Biologisk: Ipilimumab
- Procedure: Computed Tomography
- Procedure: Magnetic Resonance Imaging
- Procedure: Echocardiography Test
- Procedure: Positron Emission Tomography
- Biologisk: Nivolumab
- Stråling: Radiation Therapy
- Procedure: Biopsy Procedure
Detaljeret beskrivelse
PRIMARY OBJECTIVE:
I. To assess if radiation improves the progression free survival (PFS, phase II portion) and overall survival (OS, phase III portion) of advanced stage non-small cell lung cancer (NSCLC) patients with PD-L1 tumor proportion score (TPS) < 1% who receive immunotherapy with or without chemotherapy.
SECONDARY OBJECTIVES:
I. To estimate and compare the rates of >= grade 3-4 and all grade adverse events by Common Terminology Criteria for Adverse Events (CTCAE) version (v)5.0 between the arms.
II. To summarize and compare progression-free survival (PFS) per Response Evaluation Criteria in Solid Tumors (RECIST) between the arms.
III. To determine and compare the objective response rate (ORR) per RECIST between the arms (including at both irradiated and un-irradiated sites).
QUALITY OF LIFE (QOL) OBJECTIVE:
I. To assess the health-related QOL in both treatment arms.
CORRELATIVE SCIENCE OBJECTIVE:
I. To evaluate changes in the peripheral immune microenvironment between the arms.
OUTLINE: Patients are randomized to 1 of 2 arms.
ARM A: Patients receive nivolumab intravenously (IV) over 30 minutes on days 1 and 22 and ipilimumab IV over 30 minutes on day 1 of each cycle. Cycles repeat every 6 weeks for 24 months in the absence of disease progression or unacceptable toxicity or patients may receive standard of care systemic immunotherapy. Patients also undergo magnetic resonance imaging (MRI), computed tomography (CT), or positron emission tomography (PET) throughout the trial. Patients may undergo blood sample collection and tissue biopsy on study as well as echocardiography (ECHO) during screening.
Arm B: Patients receive nivolumab IV over 30 minutes on days 1 and 22 and ipilimumab IV over 30 minutes on day 1 of each cycle. Cycles repeat every 6 weeks for 24 months in the absence of disease progression or unacceptable toxicity or patients may receive standard of care systemic immunotherapy. Patients also undergo 3 fractions of radiation therapy every other day. Patients also undergo MRI, CT, or PET throughout the trial. Patients may undergo blood sample collection and tissue biopsy on study as well as ECHO during screening.
After completion of study treatment, patients are followed up every 3 months for 3 years and then every 6 months for years 4-5 following randomization until disease progression. Following disease progression patients are followed for survival every 6 months for up to 5 years following randomization.
Undersøgelsestype
Tilmelding (Anslået)
Fase
- Fase 2
- Fase 3
Kontakter og lokationer
Studiesteder
-
-
Arizona
-
Phoenix, Arizona, Forenede Stater, 85054
- Mayo Clinic Hospital in Arizona
-
-
Arkansas
-
Little Rock, Arkansas, Forenede Stater, 72205
- University of Arkansas for Medical Sciences
-
-
California
-
Berkeley, California, Forenede Stater, 94704
- Alta Bates Summit Medical Center-Herrick Campus
-
Duarte, California, Forenede Stater, 91010
- City of Hope Comprehensive Cancer Center
-
Irvine, California, Forenede Stater, 92618
- City of Hope at Irvine Lennar
-
Lancaster, California, Forenede Stater, 93534
- City of Hope Antelope Valley
-
Marysville, California, Forenede Stater, 95901
- Fremont - Rideout Cancer Center
-
Modesto, California, Forenede Stater, 95355
- Memorial Medical Center
-
Napa, California, Forenede Stater, 94558
- Providence Queen of The Valley
-
Sacramento, California, Forenede Stater, 95817
- University of California Davis Comprehensive Cancer Center
-
South Pasadena, California, Forenede Stater, 91030
- City of Hope South Pasadena
-
Truckee, California, Forenede Stater, 96161
- Gene Upshaw Memorial Tahoe Forest Cancer Center
-
Upland, California, Forenede Stater, 91786
- City of Hope Upland
-
-
Colorado
-
Colorado Springs, Colorado, Forenede Stater, 80909
- UCHealth Memorial Hospital Central
-
Colorado Springs, Colorado, Forenede Stater, 80920
- Memorial Hospital North
-
Fort Collins, Colorado, Forenede Stater, 80524
- Poudre Valley Hospital
-
Fort Collins, Colorado, Forenede Stater, 80528
- Cancer Care and Hematology-Fort Collins
-
Greeley, Colorado, Forenede Stater, 80631
- UCHealth Greeley Hospital
-
Loveland, Colorado, Forenede Stater, 80538
- Medical Center of the Rockies
-
-
Delaware
-
Millville, Delaware, Forenede Stater, 19967
- Beebe South Coastal Health Campus
-
Newark, Delaware, Forenede Stater, 19713
- Helen F Graham Cancer Center
-
Newark, Delaware, Forenede Stater, 19713
- Medical Oncology Hematology Consultants PA
-
Rehoboth Beach, Delaware, Forenede Stater, 19971
- Beebe Health Campus
-
-
District of Columbia
-
Washington D.C., District of Columbia, Forenede Stater, 20010
- MedStar Washington Hospital Center
-
-
Florida
-
Aventura, Florida, Forenede Stater, 33180
- UM Sylvester Comprehensive Cancer Center at Aventura
-
Clearwater, Florida, Forenede Stater, 33756
- Morton Plant Hospital
-
Coral Gables, Florida, Forenede Stater, 33146
- UM Sylvester Comprehensive Cancer Center at Coral Gables
-
Deerfield Beach, Florida, Forenede Stater, 33442
- UM Sylvester Comprehensive Cancer Center at Deerfield Beach
-
Miami, Florida, Forenede Stater, 33136
- University of Miami Miller School of Medicine-Sylvester Cancer Center
-
Miami, Florida, Forenede Stater, 33176
- UM Sylvester Comprehensive Cancer Center at Kendall
-
Plantation, Florida, Forenede Stater, 33324
- UM Sylvester Comprehensive Cancer Center at Plantation
-
Tampa, Florida, Forenede Stater, 33607
- Saint Joseph's Hospital/Children's Hospital-Tampa
-
Winter Haven, Florida, Forenede Stater, 33881
- Winter Haven Hospital
-
-
Georgia
-
Newnan, Georgia, Forenede Stater, 30265
- CTCA at Southeastern Regional Medical Center
-
Savannah, Georgia, Forenede Stater, 31405
- Lewis Cancer and Research Pavilion at Saint Joseph's/Candler
-
-
Idaho
-
Boise, Idaho, Forenede Stater, 83712
- Saint Luke's Cancer Institute - Boise
-
Fruitland, Idaho, Forenede Stater, 83619
- Saint Luke's Cancer Institute - Fruitland
-
Meridian, Idaho, Forenede Stater, 83642
- Saint Luke's Cancer Institute - Meridian
-
Nampa, Idaho, Forenede Stater, 83687
- Saint Luke's Cancer Institute - Nampa
-
Twin Falls, Idaho, Forenede Stater, 83301
- Saint Luke's Cancer Institute - Twin Falls
-
-
Illinois
-
Chicago, Illinois, Forenede Stater, 60611
- Northwestern University
-
Chicago, Illinois, Forenede Stater, 60637
- University of Chicago Comprehensive Cancer Center
-
Chicago, Illinois, Forenede Stater, 60612
- University of Illinois
-
Danville, Illinois, Forenede Stater, 61832
- Carle at The Riverfront
-
DeKalb, Illinois, Forenede Stater, 60115
- Northwestern Medicine Cancer Center Kishwaukee
-
Decatur, Illinois, Forenede Stater, 62526
- Decatur Memorial Hospital
-
Effingham, Illinois, Forenede Stater, 62401
- Crossroads Cancer Center
-
Effingham, Illinois, Forenede Stater, 62401
- Carle Physician Group-Effingham
-
Geneva, Illinois, Forenede Stater, 60134
- Northwestern Medicine Cancer Center Delnor
-
Glenview, Illinois, Forenede Stater, 60026
- Northwestern Medicine Glenview Outpatient Center
-
Grayslake, Illinois, Forenede Stater, 60030
- Northwestern Medicine Grayslake Outpatient Center
-
Harvey, Illinois, Forenede Stater, 60426
- Ingalls Memorial Hospital
-
Lake Forest, Illinois, Forenede Stater, 60045
- Northwestern Medicine Lake Forest Hospital
-
Mattoon, Illinois, Forenede Stater, 61938
- Carle Physician Group-Mattoon/Charleston
-
New Lenox, Illinois, Forenede Stater, 60451
- UC Comprehensive Cancer Center at Silver Cross
-
O'Fallon, Illinois, Forenede Stater, 62269
- HSHS Saint Elizabeth's Hospital
-
Orland Park, Illinois, Forenede Stater, 60462
- University of Chicago Medicine-Orland Park
-
Rockford, Illinois, Forenede Stater, 61114
- UW Health Carbone Cancer Center Rockford
-
Springfield, Illinois, Forenede Stater, 62702
- Southern Illinois University School of Medicine
-
Springfield, Illinois, Forenede Stater, 62702
- Springfield Clinic
-
Springfield, Illinois, Forenede Stater, 62781
- Springfield Memorial Hospital
-
Urbana, Illinois, Forenede Stater, 61801
- Carle Cancer Center
-
Warrenville, Illinois, Forenede Stater, 60555
- Northwestern Medicine Cancer Center Warrenville
-
-
Indiana
-
Crown Point, Indiana, Forenede Stater, 46307
- UChicago Medicine Northwest Indiana
-
-
Iowa
-
Ames, Iowa, Forenede Stater, 50010
- Mary Greeley Medical Center
-
Ames, Iowa, Forenede Stater, 50010
- McFarland Clinic - Ames
-
Ankeny, Iowa, Forenede Stater, 50023
- UI Health Care Mission Cancer and Blood - Ankeny Clinic
-
Clive, Iowa, Forenede Stater, 50325
- Mercy Cancer Center-West Lakes
-
Clive, Iowa, Forenede Stater, 50325
- UI Health Care Mission Cancer and Blood - West Des Moines Clinic
-
Creston, Iowa, Forenede Stater, 50801
- Greater Regional Medical Center
-
Des Moines, Iowa, Forenede Stater, 50309
- Iowa Methodist Medical Center
-
Des Moines, Iowa, Forenede Stater, 50314
- Mercy Medical Center - Des Moines
-
Des Moines, Iowa, Forenede Stater, 50309
- UI Health Care Mission Cancer and Blood - Des Moines Clinic
-
Des Moines, Iowa, Forenede Stater, 50314
- UI Health Care Mission Cancer and Blood - Laurel Clinic
-
Waukee, Iowa, Forenede Stater, 50263
- UI Health Care Mission Cancer and Blood - Waukee Clinic
-
West Des Moines, Iowa, Forenede Stater, 50266
- Mercy Medical Center-West Lakes
-
West Des Moines, Iowa, Forenede Stater, 50266
- The Iowa Clinic PC
-
-
Kentucky
-
Lexington, Kentucky, Forenede Stater, 40536
- University of Kentucky/Markey Cancer Center
-
Lexington, Kentucky, Forenede Stater, 40509
- CommonSpirit Saint Joseph Medical Center - East Lexington
-
-
Maine
-
Sanford, Maine, Forenede Stater, 04073
- MaineHealth Cancer Care Center of York County
-
Scarborough, Maine, Forenede Stater, 04074
- MaineHealth Maine Medical Center- Scarborough
-
South Portland, Maine, Forenede Stater, 04106
- MaineHealth Cancer Care and IV Therapy - South Portland
-
-
Michigan
-
Ann Arbor, Michigan, Forenede Stater, 48106
- Trinity Health Saint Joseph Mercy Hospital Ann Arbor
-
Brighton, Michigan, Forenede Stater, 48114
- Trinity Health IHA Medical Group Hematology Oncology - Brighton
-
Brighton, Michigan, Forenede Stater, 48114
- Trinity Health Medical Center - Brighton
-
Canton, Michigan, Forenede Stater, 48188
- Trinity Health IHA Medical Group Hematology Oncology - Canton
-
Canton, Michigan, Forenede Stater, 48188
- Trinity Health Medical Center - Canton
-
Chelsea, Michigan, Forenede Stater, 48118
- Trinity Health IHA Medical Group Hematology Oncology - Chelsea Hospital
-
Chelsea, Michigan, Forenede Stater, 48118
- Chelsea Hospital
-
Flint, Michigan, Forenede Stater, 48503
- Hurley Medical Center
-
Flint, Michigan, Forenede Stater, 48503
- Genesys Hurley Cancer Institute
-
Kalamazoo, Michigan, Forenede Stater, 49007
- West Michigan Cancer Center
-
Kalamazoo, Michigan, Forenede Stater, 49007
- Bronson Methodist Hospital
-
Lansing, Michigan, Forenede Stater, 48912
- University of Michigan Health - Sparrow Lansing
-
Livonia, Michigan, Forenede Stater, 48154
- Trinity Health Saint Mary Mercy Livonia Hospital
-
Pontiac, Michigan, Forenede Stater, 48341
- Trinity Health Saint Joseph Mercy Oakland Hospital
-
Pontiac, Michigan, Forenede Stater, 48341
- Michigan Healthcare Professionals Pontiac
-
Saginaw, Michigan, Forenede Stater, 48604
- Oncology Hematology Associates of Saginaw Valley PC
-
Saginaw, Michigan, Forenede Stater, 48601
- MyMichigan Medical Center Saginaw
-
Tawas City, Michigan, Forenede Stater, 48764
- MyMichigan Medical Center Tawas
-
West Branch, Michigan, Forenede Stater, 48661
- Saint Mary's Oncology/Hematology Associates of West Branch
-
Ypsilanti, Michigan, Forenede Stater, 48197
- Trinity Health IHA Medical Group Hematology Oncology Ann Arbor Campus
-
-
Minnesota
-
Duluth, Minnesota, Forenede Stater, 55805
- Miller-Dwan Hospital
-
Minneapolis, Minnesota, Forenede Stater, 55415
- Hennepin County Medical Center
-
Robbinsdale, Minnesota, Forenede Stater, 55422
- North Memorial Medical Health Center
-
Saint Cloud, Minnesota, Forenede Stater, 56303
- Coborn Cancer Center at Saint Cloud Hospital
-
Saint Paul, Minnesota, Forenede Stater, 55101
- Regions Hospital
-
-
Missouri
-
Cape Girardeau, Missouri, Forenede Stater, 63703
- Saint Francis Medical Center
-
Farmington, Missouri, Forenede Stater, 63640
- Parkland Health Center - Farmington
-
Rolla, Missouri, Forenede Stater, 65401
- Phelps Health Delbert Day Cancer Institute
-
Sainte Genevieve, Missouri, Forenede Stater, 63670
- Sainte Genevieve County Memorial Hospital
-
Springfield, Missouri, Forenede Stater, 65804
- Mercy Hospital Springfield
-
St Louis, Missouri, Forenede Stater, 63131
- Missouri Baptist Medical Center
-
St Louis, Missouri, Forenede Stater, 63141
- Mercy Hospital Saint Louis
-
St Louis, Missouri, Forenede Stater, 63128
- Mercy Hospital South
-
Sullivan, Missouri, Forenede Stater, 63080
- Missouri Baptist Sullivan Hospital
-
-
Montana
-
Bozeman, Montana, Forenede Stater, 59715
- Bozeman Health Deaconess Hospital
-
-
New York
-
Buffalo, New York, Forenede Stater, 14263
- Roswell Park Cancer Institute
-
Lake Success, New York, Forenede Stater, 11042
- Northwell Health/Center for Advanced Medicine
-
New York, New York, Forenede Stater, 10019
- Mount Sinai West
-
New York, New York, Forenede Stater, 10029
- Mount Sinai Hospital
-
New York, New York, Forenede Stater, 10011
- Mount Sinai Chelsea
-
New York, New York, Forenede Stater, 10075
- Lenox Hill Hospital
-
New York, New York, Forenede Stater, 10065
- Manhattan Eye Ear and Throat Hospital
-
Oswego, New York, Forenede Stater, 13126
- Upstate Cancer Center at Oswego
-
Oswego, New York, Forenede Stater, 13126
- Upstate Cancer Center Radiation Oncology at Oswego
-
Syracuse, New York, Forenede Stater, 13210
- State University of New York Upstate Medical University
-
Syracuse, New York, Forenede Stater, 13215
- SUNY Upstate Medical Center-Community Campus
-
Syracuse, New York, Forenede Stater, 13210
- Upstate Cancer Center at Hill Radiation Oncology
-
Verona, New York, Forenede Stater, 13478
- Upstate Cancer Center at Verona
-
-
North Carolina
-
Durham, North Carolina, Forenede Stater, 27710
- Duke University Medical Center
-
Raleigh, North Carolina, Forenede Stater, 27609
- Duke Cancer Center Raleigh
-
Winston-Salem, North Carolina, Forenede Stater, 27157
- Wake Forest University Health Sciences
-
-
Ohio
-
Akron, Ohio, Forenede Stater, 44304
- Summa Health System - Akron Campus
-
-
Oklahoma
-
Lawton, Oklahoma, Forenede Stater, 73505
- Cancer Centers of Southwest Oklahoma Research
-
Oklahoma City, Oklahoma, Forenede Stater, 73104
- University of Oklahoma Health Sciences Center
-
Oklahoma City, Oklahoma, Forenede Stater, 73120
- Mercy Hospital Oklahoma City
-
-
Oregon
-
Gresham, Oregon, Forenede Stater, 97030
- Legacy Mount Hood Medical Center
-
Portland, Oregon, Forenede Stater, 97239
- Oregon Health and Science University
-
Portland, Oregon, Forenede Stater, 97210
- Legacy Good Samaritan Hospital and Medical Center
-
Tualatin, Oregon, Forenede Stater, 97062
- Legacy Meridian Park Hospital
-
-
Pennsylvania
-
Chadds Ford, Pennsylvania, Forenede Stater, 19317
- Christiana Care Health System-Concord Health Center
-
Danville, Pennsylvania, Forenede Stater, 17822
- Geisinger Medical Center
-
Hershey, Pennsylvania, Forenede Stater, 17033-0850
- Penn State Milton S Hershey Medical Center
-
Lewisburg, Pennsylvania, Forenede Stater, 17837
- Geisinger Medical Oncology-Lewisburg
-
Reading, Pennsylvania, Forenede Stater, 19605
- Penn State Health Saint Joseph Medical Center
-
Wilkes-Barre, Pennsylvania, Forenede Stater, 18711
- Geisinger Wyoming Valley/Henry Cancer Center
-
-
South Carolina
-
Charleston, South Carolina, Forenede Stater, 29425
- Medical University of South Carolina
-
-
Texas
-
Amarillo, Texas, Forenede Stater, 79106
- The Don and Sybil Harrington Cancer Center
-
-
Virginia
-
Richmond, Virginia, Forenede Stater, 23235
- VCU Massey Cancer Center at Stony Point
-
Richmond, Virginia, Forenede Stater, 23298
- VCU Massey Comprehensive Cancer Center
-
Tappahannock, Virginia, Forenede Stater, 22560
- VCU Health Tappahannock Hospital
-
-
Washington
-
Vancouver, Washington, Forenede Stater, 98686
- Legacy Salmon Creek Hospital
-
Vancouver, Washington, Forenede Stater, 98684
- Legacy Cancer Institute Medical Oncology and Day Treatment
-
Walla Walla, Washington, Forenede Stater, 99362
- Providence Saint Mary Regional Cancer Center
-
-
West Virginia
-
Charleston, West Virginia, Forenede Stater, 25304
- Vandalia Health/CAMC Institute for Academic Medicine
-
-
Wisconsin
-
Ashland, Wisconsin, Forenede Stater, 54806
- Northwest Wisconsin Cancer Center
-
Eau Claire, Wisconsin, Forenede Stater, 54701
- Marshfield Medical Center-EC Cancer Center
-
La Crosse, Wisconsin, Forenede Stater, 54601
- Gundersen Lutheran Medical Center
-
La Crosse, Wisconsin, Forenede Stater, 54601
- Mayo Clinic Health System-Franciscan Healthcare
-
Marshfield, Wisconsin, Forenede Stater, 54449
- Marshfield Medical Center-Marshfield
-
Minocqua, Wisconsin, Forenede Stater, 54548
- Marshfield Medical Center - Minocqua
-
Mukwonago, Wisconsin, Forenede Stater, 53149
- ProHealth D N Greenwald Center
-
New Richmond, Wisconsin, Forenede Stater, 54017
- Cancer Center of Western Wisconsin
-
Oconomowoc, Wisconsin, Forenede Stater, 53066
- ProHealth Oconomowoc Memorial Hospital
-
Rice Lake, Wisconsin, Forenede Stater, 54868
- Marshfield Medical Center-Rice Lake
-
Stevens Point, Wisconsin, Forenede Stater, 54482
- Marshfield Medical Center-River Region at Stevens Point
-
Waukesha, Wisconsin, Forenede Stater, 53188
- UW Cancer Center at ProHealth Care
-
Weston, Wisconsin, Forenede Stater, 54476
- Marshfield Medical Center - Weston
-
-
Deltagelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
Inclusion Criteria:
- Histologic or cytologic diagnosis of stage IV NSCLC using version American Joint Committee on Cancer (AJCC) 8th edition (includes M1a, M1b, and M1c stage disease). Patients with stage IIIB and IIIC disease are eligible if they are not a candidate for combined chemotherapy and radiation
- PD-L1 expression tumor proportion score (TPS) < 1% in tumor cells. If PD-L1 expression TPS is unevaluable or the testing could not be completed patients are not eligible. The assay must have been performed locally by a Clinical Laboratory Improvement Act (CLIA) (or equivalent) certified laboratory. The type of assay will be recorded
- For non-squamous patients only (adenocarcinoma or adenosquamous): EGFR, ALK and ROS1 testing must be done locally. No patients with known actionable EGFR mutations (except exon 20 insertion), ALK or ROS1 mutations that can be treated with oral tyrosine inhibitors
- Measurable disease based on RECIST 1.1, including at least two cancerous deposits. At least one deposit must be RECIST measurable (and not to be irradiated) while at least one OTHER deposit (measurable or non-measurable) must meet criteria for three 8 gray (Gy) doses of radiation
- Age >= 18 years
- Eastern Cooperative Oncology Group (ECOG) performance status 0-2
- No more than three weeks of treatment with systemic chemotherapy or immunotherapy for advanced NSCLC
- No more than three weeks of treatment with checkpoint inhibitors for metastatic lung cancer
- No treatment with chemotherapy or immunotherapy for non-metastatic disease (e.g., adjuvant therapy) within 6 months prior to registration
- No systemic immunostimulatory or immunosuppressive drugs, including > 10 mg prednisone equivalent per day, within 2 weeks or 5 half-live of the drug, whichever is shorter. Steroid premedication per local standard is allowed
- >= 1 week prior to registration since palliative (including central nervous system [CNS]) radiotherapy to any tumor site
- No prior allogeneic tissue/solid organ transplant
- No uncontrolled intercurrent illness including, but not limited to, serious ongoing or active infection, symptomatic congestive heart failure, uncontrolled cardiac arrhythmia, unstable angina pectoris, that would limit compliance with study requirements
- No current pneumonitis or history of non-infectious pneumonitis that required steroids
- Human immunodeficiency virus (HIV)-infected patients on effective anti-retroviral therapy with undetectable viral load within 6 months of registration
- No active auto-immune disease that requires systemic therapy within 2 years prior to registration. Replacement therapy (e.g., thyroxine, insulin, or physiologic corticosteroid release therapy for adrenal or pituitary insufficiency) is not considered a form of systemic treatment and is allowed
- No known history of hepatitis B (defined as hepatitis B surface antigen [HBsAg] reactive) or known hepatitis C virus (defined as HCV ribonucleic acid [RNA] [qualitative] is detected) infection
- No patients with symptomatic central nervous system metastases and/or carcinomatous meningitis. Patients with small asymptomatic brain metastases are eligible as are patients with treated brain metastases that require no steroids
- Not pregnant and not nursing, because this study involves radiation as well as potentially chemotherapy which have known genotoxic, mutagenic and teratogenic effects. Therefore, for women of childbearing potential only, a negative urine or serum pregnancy test done =< 7 days prior to registration is required
- No patients with a "currently active" second malignancy that is progressing or has required active treatment within the last 2 years. Participants with non-melanoma skin cancers or carcinoma in-situ (e.g., breast carcinoma, urothelial carcinoma or cervical cancer in situ) or localized prostate cancer (T1-3, N0, M0) that have undergone potentially curative therapy are eligible
- No hypersensitivity (>= grade 3) to immunotherapy and/or any of its excipients
- No live vaccine within 30 days prior to registration. Examples of live vaccines include, but are not limited to, the following: measles, mumps, rubella, varicella/zoster (chicken pox), yellow fever, rabies, Bacillus Calmette-Guerin (BCG), and typhoid vaccine. Seasonal influenza vaccines for injection are generally killed virus vaccines and are allowed; however, intranasal influenza vaccines (e.g.,FluMist [registered trademark]) are live attenuated vaccines and are not allowed. COVID-19 vaccine is allowed
- Absolute neutrophil count (ANC) >= 1,500/mm^3
- Platelet count >= 100,000/mm^3
- Calculated (Calc.) creatinine clearance >= 45 mL/min
- Total bilirubin =< 1.5 x upper limit of normal (ULN)
- Aspartate aminotransferase (AST) / alanine aminotransferase (ALT) =< 2.5 x upper limit of normal (ULN)
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Behandling
- Tildeling: Randomiseret
- Interventionel model: Parallel tildeling
- Maskning: Ingen (Åben etiket)
Våben og indgreb
Deltagergruppe / Arm |
Intervention / Behandling |
|---|---|
|
Eksperimentel: Arm A (immunotherapy, +/- chemotherapy)
Patients receive nivolumab intravenously (IV) over 30 minutes on days 1 and 22 and ipilimumab IV over 30 minutes on day 1 of each cycle. Cycles repeat every 6 weeks for 24 months in the absence of disease progression or unacceptable toxicity or patients may receive standard of care systemic immunotherapy. Patients also undergo MRI, CT, or PET throughout the trial. Patients may undergo blood sample collection and tissue biopsy on study as well as ECHO during screening. |
Ancillary studies
Andre navne:
Undergo blood sample collection
Andre navne:
Given IV
Andre navne:
Undergo CT
Andre navne:
Undergo MRI
Andre navne:
Undergo ECHO
Andre navne:
Undergo PET
Andre navne:
Given IV
Andre navne:
Undergo tissue biopsy
Andre navne:
|
|
Eksperimentel: Arm B (immunotherapy, +/- chemotherapy, radiation therapy)
Patients receive 1 of 6 treatment options as in Arm A. Patients also undergo 3 fractions of radiation therapy every other day. Patients also undergo MRI, CT, or PET throughout the trial. Patients may undergo blood sample collection and tissue biopsy on study as well as ECHO during screening. |
Ancillary studies
Andre navne:
Undergo blood sample collection
Andre navne:
Given IV
Andre navne:
Undergo CT
Andre navne:
Undergo MRI
Andre navne:
Undergo ECHO
Andre navne:
Undergo PET
Andre navne:
Given IV
Andre navne:
Undergo radiation therapy
Andre navne:
Undergo tissue biopsy
Andre navne:
|
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Progression-free survival (PFS) (Phase II)
Tidsramme: From randomization to disease progression or death of all causes, whichever comes first, assessed up to 5 years
|
Will be performed on an intent-to-treat (ITT) basis. |
From randomization to disease progression or death of all causes, whichever comes first, assessed up to 5 years
|
|
Overall survival (OS) (Phase III)
Tidsramme: From randomization and death of all causes, assessed up to 5 years
|
Will be performed on an ITT basis. The comparison of the distributions of OS between treatment arms will be done with a one-sided stratified log-rank test). The rates at various time points (e.g., every 6 months after randomization) and medians of OS for each arm will be estimated using the Kaplan-Meier estimator. The associated 95% confidence interval (CI) will be calculated using Greenwood's formula and based on a log-log transformation applied on the survival function. Hazard ratios will be estimated using a stratified Cox regression model. The final phase III analysis of OS will be considered as "positive" if the stratified log-rank test statistics Z-value greater than the critical value adjusted for type 1 error using group sequential methods. Multivariable Cox models will be used to evaluate the treatment effect on survival time and its interaction with baseline covariates, including stage, systemic therapy, histology and performance status. |
From randomization and death of all causes, assessed up to 5 years
|
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Livskvalitet
Tidsramme: Op til 5 år
|
Op til 5 år
|
|
|
PFS
Tidsramme: From randomization to disease progression or death of all causes, whichever comes first, assessed up to 5 years
|
Assessed per Response Evaluation Criteria in Solid Tumors (RECIST). |
From randomization to disease progression or death of all causes, whichever comes first, assessed up to 5 years
|
|
Objective response rate (ORR)
Tidsramme: Up to 5 years
|
Assessed per RECIST for both irradiated and un-irradiated areas. The ORRs between treatments will be compared with Fisher's exact test. The difference of ORR between treatments will be estimated by the Miettinen-Nurminen method and its 95% CI will be given. Multivariable logistic regression will be used to evaluate the treatment effect on ORR while adjusting for significant baseline covariates. |
Up to 5 years
|
|
Incidence of treatment-related adverse events
Tidsramme: Up to 5 years
|
Treatment-related toxicity will be summarized by grade, type, and system organ class. Comparisons of the percentages of patients experiencing an adverse event between Arm A and Arm B will be performed using Fisher's exact test. |
Up to 5 years
|
Samarbejdspartnere og efterforskere
Sponsor
Efterforskere
- Ledende efterforsker: Christine M Bestvina, Alliance for Clinical Trials in Oncology
Publikationer og nyttige links
Datoer for undersøgelser
Studer store datoer
Studiestart (Faktiske)
Primær færdiggørelse (Anslået)
Studieafslutning (Anslået)
Datoer for studieregistrering
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først opslået (Faktiske)
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Yderligere relevante MeSH-vilkår
- Neoplasmer efter sted
- Neoplasmer
- Luftvejssygdomme
- Neoplasmer efter histologisk type
- Lungesygdomme
- Neoplasmer, kirtel og epitel
- Adenocarcinom
- Neoplasmer i luftvejene
- Thoracale neoplasmer
- Karcinom
- Karcinom, bronkogent
- Bronkiale neoplasmer
- Adenocarcinom i lunge
- Lungeneoplasmer
- Karcinom, ikke-småcellet lunge
- Aminosyrer, peptider og proteiner
- Proteiner
- Undersøgelsesteknikker
- Terapeutik
- Kliniske laboratorieteknikker
- Diagnostiske teknikker og procedurer
- Diagnose
- Kirurgiske procedurer, operative
- Cytologiske teknikker
- Cytodiagnose
- Biologiske faktorer
- Fysiske fænomener
- Antistoffer, monoklonal, humaniseret
- Antistoffer, monoklonal
- Antistoffer
- Immunoglobuliner
- Immunoproteiner
- Blodproteiner
- Serum globuliner
- Globuliner
- Diagnostiske teknikker, kirurgisk
- Kemiteknikker, analytisk
- Spektrumanalyse
- Receptorer, celleoverflade
- Membranproteiner
- Antigener
- Antigener, overflade
- Biomarkører
- Receptorer, immunologisk
- Antigener, differentiering, T-lymfocyt
- Antigener, differentiering
- Immune kontrolpunktsproteiner
- Costimulerende og inhiberende T-celle-receptorer
- Nivolumab
- Ipilimumab
- Strålebehandling
- Stråling
- Biopsi
- Håndtering af eksemplar
- Magnetisk resonansspektroskopi
- CTLA-4-antigen
Andre undersøgelses-id-numre
- NCI-2021-06042
- U10CA180821 (U.S. NIH-bevilling/kontrakt)
- NCI-2021-06042 (Registry Identifier: CTRP (Clinical Trial Reporting Program))
- A082002 (Anden identifikator: CTEP)
- A082002 (Anden identifikator: Alliance for Clinical Trials in Oncology)
Plan for individuelle deltagerdata (IPD)
Planlægger du at dele individuelle deltagerdata (IPD)?
IPD-planbeskrivelse
NCI is committed to sharing data in accordance with NIH policy. For more details on how clinical trial data is shared, access the link to the NIH data sharing policy page.
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Studerer et amerikansk FDA-reguleret enhedsprodukt
produkt fremstillet i og eksporteret fra U.S.A.
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .